Common Stock, $0.01 par value
- Symbol
- AXGN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Axogen, Inc.
AXGNNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 1, 2026, Axogen, Inc. (the “Company”) issued a press release announcing the completion of its previously announced acquisition of BioCircuit Technologies, Inc (the “Acquisition”). The Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a press release announcing its entry into closing of the Acquisition.…
Recent company filings
- 424B5 filingSep 10, 2026
- Entry into a Material Definitive Agreement · Regulation FD DisclosureSep 10, 2026
- Entry into a Material Definitive Agreement · Regulation FD Disclosure · Other EventsSep 10, 2026
- 144 filingSep 2, 2026
- SCHEDULE 13G/A - filed by First Light Asset Management, LLC regarding Axogen, Inc.Aug 14, 2026
Registered securities in this filing
AXOGEN, INC. · 8-K · Filed 2026-10-01
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On October 1, 2026, Axogen, Inc. (the “Company”) issued a press release announcing the completion of its previously announced acquisition of BioCircuit Technologies, Inc (the “Acquisition”).
The Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a press release announcing its entry into closing of the Acquisition.
The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.